April 8, 2022
Meiji Seika Pharma said on April 7 that the first patient has been dosed in a PII clinical trial of ME3183, a selective phosphodiesterase 4 (PDE4) inhibitor, targeting patients with plaque psoriasis in the US and Canada. ME3183 is an...read more